Latest news with #PfizerLtd
Time of India
20-05-2025
- Business
- Time of India
Pfizer Q4 results: Net profit jumps 85% to Rs 330.94 crore
NEW DELHI: US pharmaceutical giant Pfizer reported an 85% surge in net profit, reaching Rs 330.94 crore during the fourth quarter ending March 2025, driven by exceptional gains from completed asset sales and transfers, the company said in a regulatory filing. The company had posted a net profit of Rs 178.86 crore in the corresponding quarter of preceding fiscal, Pfizer Ltd said in the filing. Operational revenue reached Rs 591.91 crore in the quarter under review, compared to Rs 546.63 crore in the same period last year, it added. The fourth quarter's total expenses increased to Rs 383.5 crore, up from Rs 377.9 crore in the previous year's corresponding period. The quarter included an exceptional gain of Rs 172.81 crore, resulting from the completed transfer and sale of Thane property, including structures and buildings, to Zoetis Pharmaceutical Research Pvt Ltd. For the fiscal year ending March 31, 2025, the consolidated net profit reached Rs 767.6 crore, compared to Rs 551.33 crore in FY24. The company's operational revenue for FY25 totalled Rs 2,281.35 crore, versus Rs 2,193.17 crore in FY24. The board of directors has proposed a total dividend of Rs 165 per equity share at Rs 10 each for the financial year ending March 2025. The dividend comprises a final dividend of Rs 35 per share, a special dividend of Rs 100 per share marking the company's 75th year in India, and an additional special dividend of Rs 30 per share reflecting gains from the leasehold land and building transfer. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
Mint
20-05-2025
- Business
- Mint
Pfizer share price rises 13% post Q4 Results, dividend announcement despite stock Market crash: Do you own?
Stock Market Today: Pfizer share price gained 13% in the intraday trades on Tuesday. This rise in the Pfizer share price was post Q4 Results, dividend announcement of RS 135 a share and despite stock Market crash While Pfizer Ltd had reported Rs179 crore In the corresponding quarter of the previous fiscal, or March quarter of FY24, the net profit in the March 2025 quarter saw a sharp jump to ₹ 331 crore. The same meants that in the March quarter of FY25, the company's earnings increased by 85% year-over-year (Y-o-Y). In Q4FY25, Pfizer's operating revenue increased 8.3% year over year to ₹ 591.9 crore from ₹ 546.6 crore in Q4FY24. In light of Pfizer's 75th anniversary in India, the Board of Directors has recommended a final dividend of Rs. 35/-per equity share of Rs. 10/-each (350% considering the face value of share ) and a special dividend of Rs. 100/-per equity share of Rs. 10/-each (1000% considering the face value of share). Additionally, the Board has recommended a special dividend of Rs. 30/-per equity share of Rs. 10/-each (300%) in light of the gain on the transfer of assignment of leasehold land and the building built on such land. This comes to a dividend of Rs. 165/-per equity share of Rs. 10/-each (1650% considering the face value of share) for the fiscal year ending March 31, 2025. Pfizer share price share price opened at ₹ 4698.80 on the BSE on Tuesday. At the time of opening the investor sentiment remained upbeat and Pfizer share price was already up by more than 5% compared to the previous days closing price of ₹ 4464.25. The Pfizer share price theerafter gained to intraday highs of ₹ 5049.80 and thsi meant intraday gains of more than 13%. The Pfizer share price also ended the day at close to ₹ 4945.35, which was almost 11% higher Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before taking any investment decisions.
Time of India
20-05-2025
- Business
- Time of India
Pfizer Q4 Results: Net profit jumps 85% to Rs 331 cr
Pfizer Ltd has reported an 85 per cent jump in net profit at Rs 330.94 crore in the fourth quarter ended March 2025, boosted by a gain in exceptional item from completion of asset sale and transfer. The company had posted a net profit of Rs 178.86 crore in the corresponding quarter of preceding fiscal, Pfizer Ltd said in a regulatory filing. Revenue from operations in the quarter under review stood at Rs 591.91 crore as against Rs 546.63 crore in the year-ago period, it added. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Villas For Sale in Dubai Might Surprise You Villas In Dubai | Search Ads Get Quote Undo Total expenses in the fourth quarter were higher at Rs 383.5 crore as compared to Rs 377.9 crore in the corresponding period a year ago. During the reporting quarter the company had an exceptional item gain of Rs 172.81 crore from the completion of the transfer and sale of land at Thane along with structures and buildings to Zoetis Pharmaceutical Research Pvt Ltd, the filing said. In the fiscal ended March 31, 2025 consolidated net profit was at Rs 767.6 crore as compared to Rs 551.33 crore in FY24. Live Events In FY25 revenue from operations stood at Rs 2,281.35 crore as compared to Rs 2,193.17 crore in FY24. Pfizer Ltd said its board of directors have recommended a total dividend of Rs 165 per equity share at Rs 10 each for the financial year ended March 2025. This includes a final dividend of Rs 35 per share, a special dividend of Rs 100 per share in view of the company's 75th year in India and a special dividend of Rs 30 per share in view of the gain on transfer of assignment of leasehold land and building, the filing said.
Business Standard
20-05-2025
- Business
- Business Standard
Volumes jump at Pfizer Ltd counter
Pfizer Ltd witnessed volume of 12.07 lakh shares by 14:14 IST on NSE, a 75.73 times surge over two-week average daily volume of 15933 shares BASF India Ltd, NLC India Ltd, Zensar Technologies Ltd, Newgen Software Technologies Ltd are among the other stocks to see a surge in volumes on NSE today, 20 May 2025. Pfizer Ltd witnessed volume of 12.07 lakh shares by 14:14 IST on NSE, a 75.73 times surge over two-week average daily volume of 15933 shares. The stock increased 10.90% to Rs.4,955.00. Volumes stood at 15028 shares in the last session. BASF India Ltd clocked volume of 7.26 lakh shares by 14:14 IST on NSE, a 15.18 times surge over two-week average daily volume of 47859 shares. The stock gained 8.17% to Rs.5,303.70. Volumes stood at 1.38 lakh shares in the last session. NLC India Ltd clocked volume of 167.99 lakh shares by 14:14 IST on NSE, a 14.61 times surge over two-week average daily volume of 11.50 lakh shares. The stock gained 2.14% to Rs.241.50. Volumes stood at 14.63 lakh shares in the last session. Zensar Technologies Ltd notched up volume of 131.18 lakh shares by 14:14 IST on NSE, a 13.13 fold spurt over two-week average daily volume of 9.99 lakh shares. The stock rose 6.37% to Rs.837.45. Volumes stood at 5.08 lakh shares in the last session. Newgen Software Technologies Ltd recorded volume of 57.45 lakh shares by 14:14 IST on NSE, a 10.05 times surge over two-week average daily volume of 5.72 lakh shares. The stock gained 9.64% to Rs.1,258.30. Volumes stood at 6.61 lakh shares in the last session.
India Today
20-05-2025
- Business
- India Today
Pfizer share price rises 12% today. Here's why
Shares of Pfizer Ltd rose sharply by nearly 12% on Tuesday after the company reported strong earnings for the quarter ending March stock jumped 11.91% during the day to touch a high of Rs 4,995.85 on the stock exchanges, after starting the day at Rs 4,698.80. The rally was mainly driven by a big rise in the company's net profit. Pfizer posted a net profit of Rs 330.94 crore in the January-March 2025 quarter, up 85% compared to Rs 178.86 crore in the same period last year. This sharp increase in profit came as a surprise for many market watchers and led to renewed interest in the company's total sales during the quarter also showed growth. Revenue rose 8% year-on-year to Rs 591.91 crore, as against Rs 546.63 crore in the quarter ended March the strong financial results, Pfizer also declared a large dividend for its shareholders. The company announced a total dividend of Rs 165 per share for the financial year 2024–25. This includes:A final dividend of Rs 35 per shareA special dividend of Rs 100 per share to mark 75 years of Pfizer's presence in IndiaAn additional special dividend of Rs 30 per share due to gains from transferring leasehold land and buildingsThis brings the total dividend to Rs 165 per share for a statement issued on May 19, 2025, Pfizer said, "The Board of Directors, at their meeting held on May 19, 2025, have recommended a final dividend of Rs 35 per equity share of Rs 10 each (350%), a special dividend of Rs 100 (1000%) to celebrate 75 years of Pfizer in India, and another Rs 30 (300%) as a result of the gain from leasehold asset transfer."From a technical point of view, the stock is currently trading above its 5-day, 10-day and 30-day simple moving averages. However, it remains below its 20-day, 50-day, 100-day, 150-day and 200-day averages. This means the stock has seen a short-term bounce but is yet to show long-term 14-day Relative Strength Index (RSI) of the stock stands at 83.93, which is well above the 70 mark. This level indicates that the stock is in the overbought zone, and some traders may consider booking profits in the short Beriwal, Manager – Derivatives Analyst (Equity Research) at Motilal Oswal Financial Services, told Business Today, 'The next leg of rally can be seen towards Rs 5,200, which would be a major hurdle zone and those who have bought the stock at lower levels can consider exiting. Immediate support will be at Rs 4,800.'Pfizer's stock is currently valued with a price-to-earnings (P/E) ratio of 36.86 and a price-to-book (P/B) ratio of 6.05. The earnings per share (EPS) stands at Rs 134.55 and the return on equity (RoE) is 16.41%. advertisement
